Trevor Martin

@martintrevor_

Co-founder & CEO | Fortune 40U40 | Forbes 30U30 | previously PhD; BA

Vrijeme pridruživanja: prosinac 2013.

Tweetovi

Blokirali ste korisnika/cu @martintrevor_

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @martintrevor_

  1. Prikvačeni tweet
    30. sij

    Excited to announce our oversubscribed $45M Series B to advance 's next-generation CRISPR Platform into both diagnostic and therapeutic products! A testament to the great team we're building at Mammoth and an exciting start to a busy year.

    Poništi
  2. proslijedio/la je Tweet
    31. sij

    Hot on the tail of our successful Series B announcement, we’ve opened up many new positions at Mammoth! Visit to find openings for Research Associates, Scientists, Product Development roles, & a Director of .

    Poništi
  3. proslijedio/la je Tweet
    31. sij

    Huge congrats to , , , Jennifer Doudna, and the whole Team on great progress building the platform for CRISPR Dx & Tx, and Min Cui/ Decheng, , and on Series B funding! I'm honored to join the Board.

    Poništi
  4. proslijedio/la je Tweet
    30. sij

    Mammoth Biosciences aims to be Illumina for the gene editing generation by

    Poništi
  5. proslijedio/la je Tweet
    30. sij
    Poništi
  6. proslijedio/la je Tweet
    30. sij

    Excited to share our portfolio company today announced a $45M Series B to develop the next generation of CRISPR products. We’re thrilled to support their expansion of applications for diagnostics, therapeutics + more. Read more via :

    Poništi
  7. proslijedio/la je Tweet
    Poništi
  8. proslijedio/la je Tweet
    30. sij

    Proud to announce our $45M Series B to expand our platform into therapeutics & broaden access to our IP to develop clinical applications w/ unprecedented speed/accuracy. Thanks to & all our investors. Read more via :

    Prikaži ovu nit
    Poništi
  9. proslijedio/la je Tweet
    30. sij

    Gene editing company Mammoth plans to leverage its IP position and $45M B round to expand from diagnostics to therapeutics

    Poništi
  10. proslijedio/la je Tweet
    30. sij
    Poništi
  11. proslijedio/la je Tweet
    30. sij

    Doudna-founded CRISPR upstart bags $45M for new Cas family, extends its reach into therapeutics

    Poništi
  12. proslijedio/la je Tweet
    30. sij

    . is working with to develop a quicker diagnostic test to stop the spread of the disease:

    Poništi
  13. proslijedio/la je Tweet
    30. sij

    Mammoth Biosciences Raises $45M in Series B Funding Round

    Poništi
  14. proslijedio/la je Tweet
    30. sij

    Mammoth Biosciences, a company founded by members that uses gene-editing technology Crispr for disease testing, raised $45 million—and its tech is already being used against coronavirus

    Poništi
  15. proslijedio/la je Tweet
    30. sij

    NFX company Mammoth , the world's 1st CRISPR-based disease detection platform co-Founded by , CRISPR pioneer Jennifer Doudna, + others announces a $45 Million Series B to fuel expansion into next-gen therapeutics & gene editing.

    Poništi
  16. proslijedio/la je Tweet
    30. sij
    Poništi
  17. proslijedio/la je Tweet
    28. sij

    Mammoth Co-Founder Janice Chen did a fantastic job chairing the "How CRISPR Revolutionizes Genomic Medicine" panel at ! She led a candid conversation about 's potential and the challenges behind bring impactful CRISPR technologies to market.

    Prikaži ovu nit
    Poništi
  18. proslijedio/la je Tweet
    27. sij

    The cas proteins are very careful about curating their online presence

    Poništi
  19. proslijedio/la je Tweet
    24. sij

    Last session for the day at - “How revolutionizes genomic medicine” chaired by co-founder

    Prikaži ovu nit
    Poništi
  20. proslijedio/la je Tweet
    24. sij

    We’re hiring! Do you have experience bringing to market and want to work with a collaborative and driven team? Then apply for our Product Manager position!

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·